Cancers, Vol. 12, Pages 473: Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Cancers, Vol. 12, Pages 473: Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Cancers doi: 10.3390/cancers12020473
Authors:
Tiako Meyo
Jouinot
Giroux-Leprieur
Fabre
Wislez
Alifano
Leroy
Boudou-Rouquette
Tlemsani
Khoudour
Arrondeau
Thomas-Schoemann
Blons
Mansuet-Lupo
Damotte
Vidal
Goldwasser
Alexandre
Blanchet
A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40 ligand (sCD40L) and soluble CD44 (sCD44), with survival in nivolumab-treated metastatic non-small cell lung cancer (NSCLC) patients. Plasma biomarkers were assayed at baseline and after two cycles of nivolumab. A cut-off of positivity for sPD-1, sPD-L1 and sCD40L expressions was defined as a plasma level above the lower limit of quantification. Baseline sPD-1 and sPD-L1 levels were subsequently analyzed in a control group of EGFR-mutated (Epidermal Growth Factor Receptor) NSCLC patients. Association between survival and biomarkers was investigated using Cox proportional hazard regression model. Eighty-seven patients were included (51 nivolumab-treated patients, 36 in EGFR-mutated group). In nivolumab group, basel...
Source: Cancers - Category: Cancer & Oncology Authors: Tiako Meyo Jouinot Giroux-Leprieur Fabre Wislez Alifano Leroy Boudou-Rouquette Tlemsani Khoudour Arrondeau Thomas-Schoemann Blons Mansuet-Lupo Damotte Vidal Goldwasser Alexandre Blanchet Tags: Article Source Type: research